Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anavex Life Sciences Corp. - Common Stock (NQ: AVXL )

10.47 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Anavex Life Sciences Corp. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Top Picks For 2023: Anavex Life Sciences
Anavex is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases, with encouraging results in Alzheimer’s, Parkinson’s, and Rett... 
Via Talk Markets
Tesla To $205? Here Are 10 Other Price Target Changes For Tuesday
Goldman Sachs cut Tesla, Inc. (NASDAQ: TSLA) price target from $235 to $205. Goldman Sachs analyst Mark Delaney maintained a Buy rating on the stock. Tesla shares fell 2.6% to $119.93 in pre-market... 
Via Benzinga
Here's How Much $100 Invested In Anavex Life Sciences 5 Years Ago Would Be Worth Today
Via Benzinga
Analyzing Anavex Life Sciences's Short Interest
Anavex Life Sciences's (NASDAQ:AVXL) short percent of float has risen 17.06% since its last report. The company recently reported that it has 11.91 million shares sold short, which is 15.71% of all... 
Via Benzinga
Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why
The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data. 
Via The Motley Fool
Is Anavex Life Sciences a Buy?
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Anavex Life Sciences Stock In The Last 5 Years
Via Benzinga
Anavex Catapults On Alzheimer's Results — But Math Question Clouds The Data
A math error could have clouded the drug's actual benefits. 
Via Investor's Business Daily
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,500 Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
Via Benzinga
Is Anavex Life Sciences a Smart Stock to Buy Now?
The company's Alzheimer's disease drug just succeeded in a clinical trial. Or did it? 
Via The Motley Fool
Dow Drops 100 Points; Asana Shares Plummet
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 100 points on Friday. 
Via Benzinga
Why Cracker Barrel Shares Are Trading Lower By Around 13%? Here Are 42 Stocks Moving In Friday's Mid-Day Session
Gainers Yunhong CTI Ltd. (NASDAQ: CTIB) rose 42% to $0.54 after dipping 56% on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Gold Down 1%; Samsara Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones falling around 75 points on Friday. 
Via Benzinga
Why Anavex Life Sciences Stock Is Surging Today
The biotech reported positive results from a phase 2b/3 study of its lead Alzheimer's disease candidate. 
Via The Motley Fool
Rigel Pharmaceuticals (RIGL) Stock Soars on FDA Approval News
Rigel Pharmaceuticals (RIGL) stock is heading higher on Friday after getting approval from the FDA for its leukemia treatment. 
Via InvestorPlace
Why Is Anavex Life Sciences (AVXL) Stock Up 30% Today?
Anavex Life Sciences (AVXL) stock is rocketing higher on Friday following positive results from an Alzheimer’s clinical trial. 
Via InvestorPlace
Smartsheet, Samsara, Anavex Life Sciences And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly lower, with the Dow Jones dropping over 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Dow Tumbles 300 Points After US Economy Adds 263,000 Jobs
U.S. stocks traded lower this morning, with the Dow Jones falling more than 300 points on Friday following the release of jobs data for November. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Jim Cramer Says This Stock Is Dynamite: 'I Do Not Want You To Do A Thing Other Than Ride It'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said The Williams Companies, Inc. (NYSE: WMB) is "terrific." He recommended buying the stock. 
Via Benzinga
Tesla, Apple, Anavex, Axsome, Pinduoduo: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed over 1% lower on Monday after protests in China against COVID-zero policies led to supply chain concerns. 
Via Benzinga
Why Shares of Anavex Life Sciences Slumped 23.5% on Monday
The company released its fourth-quarter and full-year numbers. 
Via The Motley Fool
Dow Tumbles 450 Points; S&P 500 Falls 1.5%
U.S. stocks traded lower toward the end of trading amid protests over COVID-19 restrictions in China. The Dow Jones dropped more than 450 points on Monday. 
Via Benzinga
Why Taboola Shares Are Trading Higher By Around 53%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Taboola.com Ltd. (NASDAQ: TBLA) shares gained 52.5% to $2.8050 after the company announced it entered into a 30-year exclusive commercial agreement with Yahoo. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Tumbles Over 200 Points; Axsome Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 200 points on Monday. 
Via Benzinga
CinCor Pharma, Anavex Life Sciences And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Earnings Scheduled For November 28, 2022
Companies Reporting Before The Bell • Pinduoduo (NASDAQ:PDD) is projected to report quarterly earnings at $0.65 per share on revenue of $4.31 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.